

Hugo Botha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9283788/publications.pdf>

Version: 2024-02-01

94
papers

2,343
citations

201674

27
h-index

254184

43
g-index

96
all docs

96
docs citations

96
times ranked

2441
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	2.4	162
2	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	2.4	133
3	The bivariate distribution of amyloid- β^2 and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
4	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	1.6	106
5	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 1144-1153.	3.9	98
6	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	3.3	81
7	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	7.6	74
8	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611. 5.3		73
9	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	7.6	67
10	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. <i>Neurology</i> , 2014, 82, 1729-1735.	1.1	63
11	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.2	63
12	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. <i>Journal of Neurology</i> , 2014, 261, 710-716.	3.6	60
13	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.1	53
14	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	11.6	52
15	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	2.7	46
16	Attention and visual dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 742-747.	2.2	45
17	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	2.9	44
18	Reliability and Diagnostic Performance of CT Imaging Criteria in the Diagnosis of Tuberculous Meningitis. <i>PLoS ONE</i> , 2012, 7, e38982.	2.5	39

#	ARTICLE	IF	CITATIONS
19	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	7.6	37
20	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	2.7	36
21	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	3.0	35
22	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	12.8	34
23	¹⁸ F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. <i>NeuroImage: Clinical</i> , 2018, 18, 897-902.	2.7	33
24	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	7.6	33
25	MRI Outperforms [¹⁸ F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	3.9	33
26	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	2.2	32
27	Sensitivity and Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	5.3	32
28	A computational model of neurodegeneration in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1643.	12.8	32
29	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	1.6	29
30	Primary Progressive Aphasias and Apraxia of Speech. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 101-127.	0.8	29
31	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.1	27
32	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 452-461.	1.5	26
33	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. <i>Neurocase</i> , 2018, 24, 111-120.	0.6	25
34	Dysphagia in Progressive Supranuclear Palsy. <i>Dysphagia</i> , 2020, 35, 667-676.	1.8	25
35	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.1	24
36	Western Aphasia Battery - Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 498-510.	1.8	24

#	ARTICLE	IF	CITATIONS
37	Comparison of 2 Dementia Screeners, the Test Your Memory Test and the Mini-Mental State Examination, in a Primary Care Setting. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 85-88.	2.3	22
38	Facial diplegia after pembrolizumab treatment. <i>Muscle and Nerve</i> , 2017, 56, E20-E21.	2.2	22
39	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 34-40.	2.2	20
40	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 56-61.	2.2	19
41	Relationships between β -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	4.2	15
42	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.3	15
43	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
44	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	3.9	14
45	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 1976-1986.	1.8	13
46	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	2.7	13
47	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. <i>European Journal of Neurology</i> , 2018, 25, 1352-1357.	3.3	12
48	loflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	3.6	12
49	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	3.6	12
50	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 1361-1372.	1.8	12
51	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	3.3	12
52	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	2.7	11
53	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	3.9	11
54	Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 436-439.	1.5	10

#	ARTICLE	IF	CITATIONS
55	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.1	10
56	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	10
57	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Neurology: Clinical Practice</i> , 2021, 11, 249-255.	1.6	9
58	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.6	8
59	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 212-217.	1.5	8
60	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. <i>NeuroImage: Clinical</i> , 2022, 35, 103030.	2.7	8
61	Longitudinal Amyloid- β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	2.6	7
62	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 392-404.	1.6	7
63	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	3.6	7
64	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.6	6
65	Autopsy Validation of Progressive Supranuclear Palsy's Predominant Speech/Language Disorder Criteria. <i>Movement Disorders</i> , 2022, 37, 213-218.	3.9	6
66	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. <i>Journal of the Acoustical Society of America</i> , 2018, 144, 3364-3370.	1.1	5
67	Longitudinal flortaucipir ([¹⁸ F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	2.4	5
68	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 17-28.	1.5	5
69	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. <i>Journal of Neurology</i> , 2021, 268, 4752-4758.	3.6	5
70	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	3.3	5
71	Consensus recommendations for the prevention of cervical cancer in sub-Saharan Africa. <i>Southern African Journal of Gynaecological Oncology</i> , 2013, 5, 47-57.	0.3	4
72	Amyloid- and tau-PET imaging in a familial prion kindred. <i>Neurology: Genetics</i> , 2018, 4, e290.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.6	4
74	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	3.9	4
75	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 9-12.	2.2	4
76	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	3.1	3
77	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.7	3
78	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	1.9	2
79	Functional Connectivity in Dementia. , 2018, , 245-266.		2
80	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. <i>American Journal of Neuroradiology</i> , 2021, , .	2.4	2
81	Clinical Reasoning: A woman with subacute progressive confusion and gait instability. <i>Neurology</i> , 2014, 83, e62-7.	1.1	1
82	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 441-451.	1.8	1
83	Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 1-11.	1.8	1
84	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. <i>Brain Sciences</i> , 2022, 12, 378.	2.3	1
85	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 193-202.	1.5	1
86	Teaching Neuro <i>Images</i> : Massive cerebral edema after CT myelography. <i>Neurology</i> , 2014, 83, e170.	1.1	0
87	A Young Man With Progressive Language Difficulty and Early-Onset Dementia. <i>JAMA Neurology</i> , 2016, 73, 595.	9.0	0
88	NeuroDebian Virtual Machine Deployment Facilitates Trainee-Driven Bedside Neuroimaging Research. <i>Journal of Child Neurology</i> , 2017, 32, 29-34.	1.4	0
89	ICâ€Pâ€028: VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P32.	0.8	0
90	P1â€442: VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P480.	0.8	0

#	ARTICLE	IF	CITATIONS
91	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. Alzheimer's and Dementia, 2019, 15, P30.	0.8	0
92	Disrupted brain dynamics across the Alzheimerâ€™s disease spectrum is related to tau accumulation. Alzheimer's and Dementia, 2020, 16, e040583.	0.8	0
93	An examination of atypical primary progressive aphasia variants. Alzheimer's and Dementia, 2021, 17, .	0.8	0
94	Posterior Cingulate Involvement Does Not Argue Against LATE. Journal of Nuclear Medicine, 2022, 63, 1282-1283.	5.0	0